Amneal Pharmaceuticals
AMRX
19.65
-0.65
-3.18%
Amneal Pharmaceuticals
US · AMRX
#1854 by market cap
Listed 1970
19.65
-0.65
-3.18%
Live - 5344 symbols - heartbeat 411s ago
· 2026-10-08 08:16
Pre-market
19.70
+0.25%
After-hours
19.65
0.00%
Overnight
19.76
+0.56%
- Market cap
- 6.28B
- P/E (TTM)i
- 40.94
- P/Bi
- 190.78
- EPSi
- 0.22
- Div yieldi
- 0.00%
- 52W posi
- 87%
Reader sentiment
Are you bullish or bearish on AMRX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 6 analysts
Buy
Avg price target
23.20 +18.1%
Price target rangecurrent 19.65
Low20.00
Avg23.20
High27.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-23 | Oppenheimer | -- | BUY | 27.00 |
| 2026-09-21 | Barclays | -- | BUY | 20.00 |
| 2026-09-21 | J.P. Morgan | -- | BUY | -- |
| 2026-09-17 | Leerink Partners | -- | BUY | 23.00 |
| 2026-09-16 | Barclays | -- | BUY | 20.00 |
| 2026-09-09 | Leerink Partners | -- | BUY | 23.00 |
| 2026-08-26 | J.P. Morgan | -- | BUY | 22.00 |
| 2026-08-10 | Goldman Sachs | -- | BUY | 21.00 |
| 2026-08-03 | UBS | -- | BUY | 25.00 |
| 2026-07-15 | UBS | -- | BUY | 23.00 |
| 2026-06-11 | UBS | -- | BUY | -- |
| 2026-06-11 | Barclays | -- | BUY | 16.00 |
| 2026-06-04 | Piper Sandler | -- | BUY | 17.00 |
| 2026-05-26 | Piper Sandler | -- | BUY | 17.00 |
| 2026-05-20 | Barclays | -- | BUY | 16.00 |
| 2026-04-23 | Truist Financial | -- | BUY | -- |
| 2026-04-17 | UBS | -- | BUY | 19.00 |
| 2026-04-16 | UBS | -- | BUY | 19.00 |
| 2026-03-18 | Barclays | -- | BUY | 15.00 |
| 2026-03-02 | Truist Financial | -- | BUY | 17.00 |
| 2026-03-02 | J.P. Morgan | -- | BUY | 18.00 |
| 2026-02-27 | Truist Financial | -- | BUY | 17.00 |
| 2026-02-11 | J.P. Morgan | -- | BUY | 18.00 |
| 2026-01-07 | Truist Financial | -- | BUY | 15.00 |
| 2025-12-08 | Barclays | -- | BUY | 15.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-30 | -- | ±15.06% | -3.14% (in line) |
| 2026/Q1 | 2026-05-01 | -- | ±15.15% | -0.31% (in line) |
| 2025/Q4 | 2026-02-27 | -- | ±14.84% | -4.69% (in line) |
| 2025/Q3 | 2025-10-30 | -- | ±12.46% | -4.12% (in line) |
| 2025/Q2 | 2025-08-05 | -- | ±14.20% | +2.14% (in line) |
| 2025/Q1 | 2025-05-02 | -- | ±14.34% | +2.97% (in line) |
| 2024/Q4 | 2025-02-28 | -- | ±24.95% | +3.46% (in line) |
| 2024/Q3 | 2024-11-08 | -- | ±12.78% | +1.39% (in line) |
| 2024/Q2 | 2024-08-09 | -- | ±15.59% | -1.54% (in line) |
| 2024/Q1 | 2024-05-03 | -- | ±24.96% | +8.86% (in line) |
| 2023/Q3 | 2023-11-07 | -- | ±31.35% | +2.38% (in line) |
| 2023/Q2 | 2023-08-04 | -- | ±20.83% | +22.32% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 08:16:04 · For reference only, not investment advice and not tailored to your situation.